How to Identify Red Flags in a Site’s Historical Trial Performance

Introduction: Why Red Flag Detection Is Essential in Feasibility

When selecting sites for a new clinical trial, evaluating historical performance is vital—but knowing what to avoid is just as important as identifying strengths. Red flags in a site’s past trial record can signal operational weaknesses, data integrity risks, or regulatory non-compliance. Ignoring these signals may lead to delays, deviations, or even sponsor audits.

Whether revealed through CTMS data, CRA notes, or inspection databases, these red flags must be incorporated into feasibility decisions. This article presents a detailed framework to identify and evaluate warning signs in a site’s trial history so sponsors and CROs can make informed, compliant, and risk-adjusted site selections.

1. Types of Red Flags in Site Historical Records

Red flags may emerge in different domains, and their severity should be considered based on context, recurrence, and mitigations:

• Enrollment issues: Underperformance or failure to meet targets without justification
• Deviation patterns: Repeated or serious protocol deviations across studies
• Regulatory findings: History of FDA 483s, Warning Letters, or MHRA/EMA inspection findings
• High screen failure or dropout rates: Suggests inadequate pre-screening or patient follow-up
• Audit trail irregularities: Missing records, backdating, or undocumented changes
• CAPA deficiencies: Failure to implement or monitor corrective actions
• Staff turnover: Frequent changes in PI or key site personnel
• Inadequate documentation: TMF gaps or non-standard recordkeeping

Any one of these may not disqualify a site alone, but when recurring or unaddressed, they signal deeper concerns.

2. Sources for Identifying Red Flags

A multifaceted review across data systems and documentation is required to uncover red flags. Key sources include:

• Clinical Trial Management System (CTMS): Past enrollment and deviation trends
• Monitoring Visit Reports: CRA observations and follow-up cycles
• Audit and QA systems: Internal audit findings, CAPA effectiveness records
• eTMF and Regulatory Docs: Delays in document submissions or missing logs
• Public databases: [FDA 483 Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/fda-inspection-database), [clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu), and other inspection records

Interviewing CRAs, project leads, and QA auditors involved in prior trials can also reveal undocumented concerns.

3. Red Flag Indicators by Trial Domain

Enrollment and Retention

• Enrolled <50% of target without documented reason
• High subject withdrawal/dropout (>20%)
• Misalignment between projected and actual enrollment timelines

Protocol Compliance

• >5 major deviations per 100 enrolled subjects
• Failure to report deviations within specified timelines
• Use of incorrect versions of ICF or CRFs

Data Quality

• Query resolution delays >7 days on average
• Inconsistencies between source data and CRF entries
• Backdating or unclear audit trails

Regulatory and Audit

• Previous FDA 483s for GCP violations
• Unresolved audit CAPAs or delayed CAPA closure
• Repeat findings across multiple audits

4. Case Study: Site Deselection Due to Deviation Pattern

During feasibility for a Phase II dermatology study, a site submitted strong infrastructure documentation and rapid IRB approval timelines. However, a review of historical records revealed the following in a prior study:

• 12 protocol deviations involving dosing errors
• 2 AE reporting delays beyond 7 days
• No documented CAPA for deviation recurrence

Despite strong feasibility responses, the sponsor excluded the site due to repeat non-compliance without evidence of learning or mitigation.

5. Sample Red Flag Evaluation Template

This allows feasibility teams to apply consistent review criteria and document selection decisions clearly.

6. Regulatory Expectations and Risk-Based Selection

Per ICH E6(R2), sponsors must adopt a quality risk management approach in selecting investigators. Key regulatory expectations include:

• Site selection must consider previous compliance history
• Known high-risk sites should be justified or excluded
• Selection documentation must be retained in the TMF
• Risk-based monitoring plans should reflect past issues

Regulators may review site selection rationale during inspections, especially for previously audited sites.

7. How to Respond When Red Flags Are Identified

Red flags do not always mean automatic exclusion. Depending on the severity and recurrence, sponsors may:

• Request CAPA documentation and PI explanation
• Include site conditionally with enhanced monitoring
• Schedule an on-site qualification audit
• Delay selection pending sponsor QA review
• Exclude site but document rationale in CTMS/TMF

Final decisions should always be documented with objective evidence and cross-functional agreement.

8. SOPs and Feasibility Tools for Red Flag Management

Your organization should incorporate red flag assessments into SOPs and feasibility templates:

• Feasibility questionnaire section for prior audit findings
• CTMS fields for deviation, dropout, and CAPA metrics
• CRA comment boxes in site selection forms
• Standard scoring system for red flag severity

Such standardization ensures consistent and transparent risk evaluation across therapeutic areas and geographies.

Conclusion

Red flags in a clinical trial site’s historical record can signal potential threats to trial quality, timelines, and regulatory standing. By systematically identifying and evaluating these indicators—using data from audits, monitoring, CTMS, and regulatory sources—sponsors and CROs can make smarter feasibility decisions and build stronger quality oversight frameworks. In an era of risk-based GCP compliance, understanding red flags is no longer optional—it is essential for inspection readiness and trial success.

Protocol Deviations Identified via eCRF Audit Trails in Clinical Trials

Introduction: The Link Between eCRFs and Protocol Compliance

Electronic Case Report Forms (eCRFs) are the backbone of data capture in clinical trials. Every data point recorded reflects protocol adherence, from dosing schedules to visit windows. Audit trails in eCRFs capture who entered or changed data, when, and why. Regulators such as the FDA, EMA, and MHRA increasingly rely on these audit trails to detect protocol deviations during inspections.

Protocol deviations identified through eCRF data often highlight discrepancies in dosing, visit schedules, laboratory assessments, or reporting timelines. Regulators classify such findings as major or critical when they affect participant safety or data integrity. For example, an FDA inspection of a Phase II oncology trial revealed that 12 protocol deviations—missed visit windows and unapproved dose adjustments—were only discovered through eCRF audit trail reviews.

Regulatory Expectations for Detecting Protocol Deviations

Agencies have clear expectations for identifying and managing protocol deviations via eCRFs:

• All data changes in eCRFs must be captured with a complete audit trail.
• Audit trails must be regularly reviewed as part of monitoring and quality assurance.
• Deviations must be documented, investigated, and categorized (major vs. minor).
• Corrective actions must be applied and reported in the Trial Master File (TMF).
• Sponsors must ensure oversight even when CROs manage eCRF systems and monitoring.

The EU Clinical Trials Register emphasizes the role of transparent deviation management in maintaining trial credibility and regulatory compliance.

Common Audit Findings Related to Protocol Deviations in eCRFs

1. Missed Visit Windows

Audit trails often reveal that patient visits occurred outside of protocol-specified windows but were not reported as deviations.

2. Unauthorized Dose Adjustments

Inspectors frequently identify dosing changes made without protocol-defined approval, documented retrospectively in eCRFs.

3. Missing Documentation of Deviations

Many deviations discovered in audit trails are not recorded in deviation logs or reported to regulators, a common audit finding.

4. CRO Oversight Failures

Sponsors often fail to verify whether CROs review audit trails consistently, leading to undetected protocol deviations.

Case Study: MHRA Audit on Protocol Deviations Detected via eCRFs

In a Phase III cardiovascular study, MHRA inspectors reviewed eCRF audit trails and identified 25 protocol deviations, including missed ECG assessments and unreported concomitant medications. The sponsor had not reconciled these deviations with site deviation logs. The finding was categorized as critical, requiring immediate CAPA and submission of updated safety analyses.

Root Causes of Protocol Deviation Audit Findings

Root cause analysis frequently identifies the following:

• Lack of SOPs mandating routine audit trail review for protocol compliance.
• Insufficient training of monitors and site staff on deviation management.
• Poor integration of eCRF systems with deviation tracking tools.
• Over-reliance on CRO monitoring without sponsor verification.
• Inadequate escalation of deviations affecting participant safety.

How to Handle Dropouts and Protocol Deviations in Clinical Trial Analysis

Dropouts and protocol deviations are almost inevitable in clinical trials. Whether due to patient withdrawal, non-adherence, or procedural inconsistencies, these events can distort the trial results if not properly handled. Regulators like the USFDA and EMA expect clear definitions and pre-specified methods for managing these issues in both the protocol and Statistical Analysis Plan (SAP).

This tutorial explains how to classify, analyze, and report dropouts and protocol deviations in a way that preserves data integrity, ensures regulatory compliance, and supports valid conclusions from your clinical trial.

What Are Dropouts and Protocol Deviations?

Dropouts:

Subjects who discontinue participation before completing the study, often due to adverse events, lack of efficacy, consent withdrawal, or personal reasons.

Protocol Deviations:

Any departure from the approved trial protocol, whether intentional or unintentional, including incorrect dosing, visit window violations, or missing assessments.

Proper classification and documentation of both are required in GMP-compliant studies.

Types of Protocol Deviations

• Major Deviations: Affect the primary endpoint or trial integrity (e.g., incorrect randomization)
• Minor Deviations: Do not impact key trial outcomes (e.g., visit outside window)
• Eligibility Deviations: Inclusion of ineligible subjects
• Treatment Deviations: Non-adherence to investigational product protocol

Major deviations usually exclude subjects from the Per Protocol (PP) analysis set but may remain in the Intent-to-Treat (ITT) set.

Statistical Approaches for Dropouts

1. Intent-to-Treat (ITT) Analysis:

Includes all randomized subjects, regardless of adherence or dropout. This approach preserves randomization benefits and is the gold standard for efficacy trials.

However, missing data due to dropouts must be addressed using methods such as:

• Mixed Models for Repeated Measures (MMRM)
• Multiple Imputation (MI)
• Pattern-Mixture Models
• Last Observation Carried Forward (LOCF) – discouraged for primary analysis

2. Per Protocol (PP) Analysis:

Includes only subjects who adhered strictly to the protocol. This provides a clearer picture of treatment efficacy under ideal conditions.

It is often used as a supportive analysis to ITT and must be predefined in the SAP and CSR.

Handling Protocol Deviations in Analysis

Deviations should be categorized and analyzed for their impact. Best practices include:

• Pre-specify major vs minor deviations in the SAP
• Perform sensitivity analysis excluding subjects with major deviations
• Justify inclusion/exclusion of deviators in each analysis set
• Report all deviations in the CSR by type and frequency

Major deviations that affect endpoints (e.g., missing primary assessments) should typically exclude those subjects from PP analysis.

Estimand Framework and Intercurrent Events

The ICH E9(R1) guideline encourages defining “intercurrent events,” which include dropouts and deviations. These are addressed through different strategies like:

• Treatment Policy: Analyze all randomized subjects regardless of intercurrent events
• Hypothetical: Model the outcome as if the event had not occurred
• Composite: Combine event with outcome into a single endpoint
• Principal Stratum: Restrict analysis to subgroup unaffected by the event

Choosing the right estimand and handling approach is a regulatory expectation and should align with trial registration strategies.

Regulatory Expectations for Dropouts and Deviations

USFDA: Emphasizes transparency in dropout handling and discourages LOCF as a primary method. Requires dropout reasons to be detailed in submission.

EMA: Requires analysis of protocol adherence and impact on efficacy interpretation. Supports multiple sensitivity analyses.

CDSCO: Encourages sponsor accountability in tracking and preventing protocol violations. Dropout management is critical during audits.

Best Practices for Managing Dropouts and Deviations

• Include dropout prevention strategies in the protocol
• Use eCRFs to track deviation type, reason, and impact
• Train sites on protocol adherence and data quality
• Implement real-time deviation monitoring dashboards
• Review deviation reports during interim data reviews

Example Scenario

In a Phase III diabetes trial, 10% of patients dropped out before the Week 24 endpoint. ITT analysis used MMRM to handle missing data, assuming MAR. A per-protocol analysis excluded 6% with major protocol deviations. Sensitivity analyses using pattern-mixture models supported the robustness of findings, as treatment effect remained statistically significant under all assumptions. The FDA approved the submission based on the transparent and well-planned analysis of dropouts and deviations.

Conclusion

Handling dropouts and protocol deviations effectively is essential for the credibility and regulatory acceptance of your clinical trial. Start with proper planning and classification, follow with appropriate statistical handling, and ensure transparent documentation. Using robust ITT and PP analyses, backed by sensitivity analyses and regulatory guidance, helps ensure that your results are reliable, unbiased, and ready for global submission.